Diathesis News and Research

RSS

Can poor diet and lifestyle behaviors modify genomic susceptibility to impulsivity?

Researchers evaluated the effects of poor diet quality and lifestyle behaviors on modifying the genomic susceptibility to impulsivity.

30 Mar 2023

Potent antibody responses to BNT162b2 COVID-19 vaccine among Japanese healthcare workers

In a paper recently uploaded to the preprint server medRxiv* by Nakajima et al. (June 4th, 2021), the antibody responses of over 2,000 Japanese healthcare workers were tracked over a period of several months, with particular regard to serum Immunoglobulin G (IgG) against the SARS-CoV-2 spike protein.

8 Jun 2021

The impact of the COVID-19 pandemic on those with OCDs

Researchers from the University Medical Centre Hamburg-Eppendorf and University Hospital, Munich in Germany, have reported their findings on the course of obsessive-compulsive disorders (OCDs) during the coronavirus disease 2019 (COVID-19) pandemic.

19 Nov 2020

LogicBio team to present data on preclinical effectiveness of GeneRide platform

LogicBio Therapeutics, Inc., a genetic medicine company founded to develop safe medicines with lasting therapeutic benefit for children with life-threatening diseases, today announced it will be presenting data on the company's technology and robust preclinical pipeline at the annual meeting of the American Society of Gene & Cell Therapy at the Hilton Chicago, from May 16-19, 2018.

14 May 2018

NYU Langone Health surgeons successfully perform first lung transplant procedure

Shortly after receiving final regulatory approval to launch a new lung transplant program, NYU Langone Health surgeons successfully performed the institution's first procedure, giving two new lungs-;and a new lease on life-;to a Brooklyn woman with a complicated form of pulmonary fibrosis.

2 Apr 2018

Genetic link to insomnia found

A new study has found certain genes that predispose a person to develop insomnia or sleep problems. This was one of the largest genome wide studies undertaken on insomnia. The study led by psychiatrist Murray Stein from the University of California San Diego was published in the latest issue of the journal Molecular Psychiatry.

13 Mar 2018

Study explores role of genes in depression vulnerability

In the current issue of Psychotherapy and Psychosomatics a study explored the role of genes in depression vulnerability. The financial crisis that has afflicted Greece since 2008 has adversely affected the physical and mental health of the population, with reports pointing to a rise in the prevalence of depression from 3.3% prior to the crisis to 12.3% in 2013.

24 Oct 2017

Impulsive children may drink less alcohol when raised in less coercive environment

Years of research have shown that impulsivity in childhood is among the individual vulnerabilities leading to substance abuse, delinquency, as well as aggressive and antisocial behavior in adolescence and adulthood.

23 Jun 2016

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company.

14 Dec 2015

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States.

9 Sep 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada.

1 Sep 2015

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII.

25 Mar 2015

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014.

16 Mar 2015

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.

10 Dec 2013

Impulsivity may be vulnerability marker for bipolar disorder

People with bipolar disorder type I are significantly more impulsive than the general population, while their siblings show an intermediate level of impulsivity, a study by Brazilian researchers shows.

29 Aug 2013

A third of depression patients convert to bipolar disorder

Around a third of patients initially diagnosed with major depressive disorder have their diagnosis changed to bipolar disorder, Polish researchers report.

8 Aug 2012

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

Regency Therapeutics, a newly established division of Luitpold Pharmaceuticals, Inc., and its co-promotion partner Daiichi Sankyo, Inc., announced today that they have launched SPRIX® (ketorolac tromethamine) Nasal Spray and that it is now commercially available.

17 May 2011

3 new genes in genetic research of suicidal behaviour

Three genes that have barely been studied to date have now provided fresh knowledge about patients with suicidal backgrounds. This is the result of a study by a team of Spanish researchers at Mount Sinai Hospital and Columbia University in the City of New York (United States), which found that several mutations are involved. This finding could help to develop future genetic tests to identify predisposition to suicide, without ignoring the importance of social and cultural factors.

16 Jun 2010

FDA approves ROXRO PHARMA's SPRIX Nasal Spray

ROXRO PHARMA, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SPRIX™ (ketorolac tromethamine) Nasal Spray, for the short-term (up to 5 days) management of acute moderate to moderately severe pain that requires analgesia at the opioid level.

17 May 2010

Study supports role of a dopamine related gene in the onset of depression

Depression is one of the most common forms of psychopathology. According to diathesis-stress theories of depression, genetic liability interacts with negative life experiences to cause depression.

16 Jan 2008